Welcome To www.LupusMCTD.com

Lupus/MCTD Discussions & InformationPhotobucket => PhotobucketResearch & Studies => Topic started by: Adminஐﻬ on October 20, 2009, 10:42:31 am



Title: Human Genome reports additional lupus drug data
Post by: Adminஐﻬ on October 20, 2009, 10:42:31 am
Human Genome reports additional lupus drug data
Tue Oct 20, 2009

Company provides more details about BLISS-52 trial
Details reinforce top-line data released in July  Company expects to announce next trial in November

Human Genome Sciences Inc
(HGSI.O) reported data on Tuesday showing its experimental lupus drug works faster than previously thought and significantly reduced the risk of disease flare-ups. The company, which released its findings at the annual American College of Rheumatology meeting in Philadelphia, saidthe drug, Benlysta, reduced the risk of disease flare-ups by 24 percent, and of severe flares by 43 percent compared with a placebo. Human Genome's shares have soared more than 500 percent since July, when it released unexpectedly positive data from a52-week, 865-patient trial known as BLISS-52. Initial data showed that 57.6 percent of patients taking the higher dose --10 milligrams per kilogram of body weight -- of Benlysta for a year experienced an improvement in symptoms, compared with 43.6 percent who took a placebo.

If approved, Benlysta, known chemically as blimumab, will be the first new drug in 50 years to treat lupus, a complex disorder that causes the immune system to attack the body's own
tissue and organs. Symptoms include achy joints, fever, arthritis, kidney damage, chest pains and skin rash. A detailed analysis of the BLISS-52 trial showed patientswho took the higher of two tested doses of Benlysta, together with current standard of care, went for an average of 119 days before experiencing a flare-up, compared with an average of 84 days for the group that took the placebo plus standard care.

The data also showed that patients had a statistically significant reduction in fatigue four to eight weeks into treatment. "These data were statistically significant and were strongly supported across multiple measures of clinical effect and multiple time-points," said David Stump, Human Genome'sexecutive vice president in charge of research and development, in a statement. Serious infections were reported in 5.9 percent of patients in the placebo group and 6.1 percent of those taking Benlysta, which is administered by infusion, the company said. On Nov. 2, Human Genome expects to announce initial results from a second 52-week trial of Benlysta known as BLISS-76. If results from the second trial mirror those of the first, the company would file for approval of the drug with U.S. regulators in early 2010. Analysts predict it could generate billions of dollars in annual sales. The company has said it expects the drug to costpatients about $20,000 a year. Human Genome is developing the drug together with GlaxoSmithKline Plc (GSK.L) and will split revenue from the drug once it is approved for sale.

SOURCE: PRESS RELEASE

Page Contents, Layout, Graphics and Design All Copyrighted by Credited Artists and are Not Public Domain.



LupusMCTD Founder & Patient
Former Domestic Violence SURVIVOR
Kathy A. Patterson

Author of the Upcoming Memoir Book:
"Fighting From The Inside Out"..
A lupus patient fights the beast within her immune system and the beast at home....

e-Booklet filled with photos and videos of what abuse was, signs to look for,
where to turn to for help, and much more to help others like me...


For more information
Call the National Domestic Violence Hotline at 1−800−799−SAFE(7233)



"The Meaning of the Words in the Second Amendment .... "That the people have a right to freedom of speech, and of writing, and publishing their sentiments;"

PRIVACY NOTICE: Warning--any person and/or institution and/or Agent and/or Agency of any governmental structure including but not limited to the United States Federal Government also using or monitoring/using this website or any of its associated websites, you do NOT have my permission to utilize any of my profile information nor any of the content contained herein including, but not limited to my photos, and/ or the comments made about my photo's or any other "picture" art posted on my profile. You are hereby notified that you are strictly prohibited from disclosing, copying, distributing, disseminating, or taking any other action against me with regard to this profile and the contents herein. The foregoing prohibitions also apply to your employee(s), agent(s), student(s) or any personnel under your direction or control. The contents of this profile are private and legally privileged and confidential information, and the violation of my personal privacy is punishable by law
Photobucket
2008 LupusMCTD Foundation of America - All Rights Reserved
Est.November 11, 2005
"We Understand What You Are Going Through"